

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis

Clinical Pharmacokinetics

Radojka M. Savic,¹ Ana M. Novakovic,² Marianne Ekblom,³ Alain Munafo,⁴ Mats O. Karlsson²

Correspondence:

Mats O Karlsson
Department of Pharmaceutical Biosciences
Uppsala University
Box 591, 751 24, Uppsala, Sweden
Email: mats.karlsson@farmbio.uu.se

Supplemental Table 1

Dose of cladribine tablets per year and week by patient body weight in the CLARITY study

| Range of body weight, kg | Dose in mg (number of 10 mg tablets) per week | |
|--------------------------|---|---------------------------------|
| | Treatment week 1 (first month) | Treatment week 2 (second month) |
| 40 to <50 | 40 mg (4 tablets) | 40 mg (4 tablets) |
| 50 to <60 | 50 mg (5 tablets) | 50 mg (5 tablets) |
| 60 to <70 | 60 mg (6 tablets) | 60 mg (6 tablets) |
| 70 to <80 | 70 mg (7 tablets) | 70 mg (7 tablets) |
| 80 to <90 | 80 mg (8 tablets) | 70 mg (7 tablets) |
| 90 to <100 | 90 mg (9 tablets) | 80 mg (8 tablets) |
| 100 to <110 | 100 mg (10 tablets) | 90 mg (9 tablets) |
| 110 and above | 100 mg (10 tablets) | 100 mg (10 tablets) |